We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.02 | -0.68% | 148.54 | 148.99 | 146.86 | 148.18 | 9,756,260 | 01:00:00 |
From Apr 2021 to Apr 2024
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Tuesday said a Phase 2b study of its respiratory syncytial virus adult vaccine candidate met all endpoints.
Janssen said the vaccine candidate was highly effective in protecting against three clinical definitions of lower respiratory tract disease caused by RSV, showing vaccine efficacy of 70% to 80% in adults ages 65 and older.
The company said the vaccine candidate was also shown to be generally well-tolerated.
Janssen said that based on the positive results from the Phase 2b study, it has initiated a global Phase 3 trial, adding that there are currently no approved vaccines or broadly indicated antivirals available, leaving older adults at high risk of developing potentially life-threatening illness from RSV.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 07, 2021 07:16 ET (12:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
